{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:44:16Z","timestamp":1781660656543,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973473"],"award-info":[{"award-number":["81973473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2019J01446"],"award-info":[{"award-number":["2019J01446"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Startup Fund for Scientific Research, Fujian Medical University","award":["2018QH1091"],"award-info":[{"award-number":["2018QH1091"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The latest published CASPIAN trial demonstrated that adding durvalumab to etoposide and platinum (EP) improved survival dramatically for patients with extensive-stage small cell lung cancer (ES-SCLC). Considering the high cost of durvalumab, this study evaluated the cost-effectiveness of durvalumab plus EP (DEP) in the first-line setting for treatment-na\u00efve patients with ES-SCLC from the U.S. payer perspective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We developed a three-state Markov model to simulate the disease course and source consumption of ES-SCLC over a lifetime horizon. Pseudo-individual patient-level data were generated from digitized Kaplan-Meier curves. Direct medical costs, including drug and administration costs, disease management and adverse events treatment fees, best supportive care and terminal care costs were obtained from sources including the Centers for Medicare and Medicaid Services, Healthcare Cost and Utilization Project, and relevant literature. Health state utility values were derived from published literature. Main outcomes considered were total costs, life-years (LYs), quality-adjusted LYs (QALYs), and incremental cost-effectiveness ratio (ICER). All costs were adjusted for inflation to reflect 2019 U.S. dollars. The willingness-to-pay threshold was set as $150,000\/QALY. One-way and probabilistic sensitivity analyses were used to explore the uncertainty of model assumptions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with EP, DEP was projected to increase life expectancy by 0.86 LYs (1.73 vs. 0.87) and 0.44 QALYs (0.93 vs. 0.49). The incremental treatment cost was $95,907, and the corresponding ICER was $216,953\/QALY. The result was most sensitive to the variation of durvalumab acquisition cost. Probabilistic sensitivity analysis revealed that the probability of DEP over EP regimen to be cost-effective was 9.4% at a willingness-to-pay threshold of $150,000\/QALY. In the case of reducing the price of durvalumab by 30.7%, DEP was more cost-effective than EP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>From the perspective of the U.S. payer, adding durvalumab to EP is estimated to be not cost-effective compared with EP alone for patients with untreated ES-SCLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>The information provided by this analysis serves as a reference for decision makers. Lowering the price of durvalumab would be a potential measure to improve the economics of durvalumab plus etoposide and platinum (DEP), and the inclusion of durvalumab in the Medicare pharmacopeia could make DEP more economically available. These results may also guide physicians and patients to choose the most economically feasible treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13954","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T10:36:21Z","timestamp":1629887781000},"page":"e2013-e2020","source":"Crossref","is-referenced-by-count":19,"title":["<scp>First-Line<\/scp> Durvalumab in Addition to Etoposide and Platinum for <scp>Extensive-Stage<\/scp> Small Cell Lung Cancer: A U.S.-Based <scp>Cost-Effectiveness<\/scp> Analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Shen","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Gu","sequence":"additional","affiliation":[{"name":"Institute for Health & Aging, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyue","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinfang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"2022011714484226100_onco13954-bib-0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What's new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"issue":"7","key":"2022011714484226100_onco13954-bib-0002","article-title":"Advances in neuroendocrine lung tumors","volume":"21","author":"Travis","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"2022011714484226100_onco13954-bib-0003","doi-asserted-by":"crossref","first-page":"e400S","DOI":"10.1378\/chest.12-2363","article-title":"Treatment of small cell lung cancer","volume":"143","author":"Jett","year":"2013","journal-title":"Chest"},{"key":"2022011714484226100_onco13954-bib-0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: Current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur Respir J"},{"key":"2022011714484226100_onco13954-bib-0005","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","article-title":"Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","volume":"25","author":"Arnold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022011714484226100_onco13954-bib-0006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the Eastern Cooperative Oncology Group (E1500)","volume":"2","author":"Pandya","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2022011714484226100_onco13954-bib-0007","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","article-title":"Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM Trial","volume":"35","author":"Tiseo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022011714484226100_onco13954-bib-0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022011714484226100_onco13954-bib-0009","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","article-title":"NCCN guidelines insights: Small cell lung cancer, version 2.2020","volume":"16","author":"Kalemkerian","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2022011714484226100_onco13954-bib-0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"2022011714484226100_onco13954-bib-0011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J Econ Perspect"},{"key":"2022011714484226100_onco13954-bib-0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2018.5449","article-title":"Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non\u2013small cell lung cancer in the context of the U.S. health care system","volume":"5","author":"Criss","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022011714484226100_onco13954-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"2022011714484226100_onco13954-bib-0014","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"2022011714484226100_onco13954-bib-0015","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"2022011714484226100_onco13954-bib-0016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: A cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022011714484226100_onco13954-bib-0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: Application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"2022011714484226100_onco13954-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2022011714484226100_onco13954-bib-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: A platform for parametric survival modelling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"Journal of Statistical Software"},{"key":"2022011714484226100_onco13954-bib-0020"},{"key":"2022011714484226100_onco13954-bib-0021","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non\u2013small cell lung cancer: A United States\u2013based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"2022011714484226100_onco13954-bib-0022","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/13696998.2018.1521416","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the U.S","volume":"21","author":"Insinga","year":"2018","journal-title":"J Med Econ"},{"key":"2022011714484226100_onco13954-bib-0023","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2017.01.005","article-title":"Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer","volume":"122","author":"Qu","year":"2017","journal-title":"Radiother Oncol"},{"key":"2022011714484226100_onco13954-bib-0024","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/03007995.2019.1571297","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the U.S","volume":"35","author":"Insinga","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2022011714484226100_onco13954-bib-0025"},{"key":"2022011714484226100_onco13954-bib-0026"},{"key":"2022011714484226100_onco13954-bib-0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.019","article-title":"Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer","volume":"130","author":"Zhou","year":"2019","journal-title":"Lung Cancer"},{"key":"2022011714484226100_onco13954-bib-0028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2018.07.012","article-title":"First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective","volume":"123","author":"Hu","year":"2018","journal-title":"Lung Cancer"},{"key":"2022011714484226100_onco13954-bib-0029","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2022011714484226100_onco13954-bib-0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022011714484226100_onco13954-bib-0031","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"2022011714484226100_onco13954-bib-0032","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","article-title":"First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: A cost-effectiveness analysis from China","volume":"132","author":"Li","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"2022011714484226100_onco13954-bib-0033"},{"key":"2022011714484226100_onco13954-bib-0034"},{"key":"2022011714484226100_onco13954-bib-0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non-small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"2022011714484226100_onco13954-bib-0036","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","article-title":"Health state utilities associated with attributes of treatments for hepatitis C","volume":"16","author":"Matza","year":"2015","journal-title":"Eur J Health Econ"},{"key":"2022011714484226100_onco13954-bib-0037","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: An international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2013\/42204116\/oncolo_26_11_e2013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2013\/42204116\/oncolo_26_11_e2013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:49:25Z","timestamp":1642430965000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/e2013\/6508809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,12]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13954","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,9,12]]}}}